Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis

Journal of Infectious Diseases

Volumn 174, Issue 5, 1996, Pages 1127-1130

  Xu, Chen ^b   Kreiswirth, Barry N ^b   Sreevatsan, Srinand ^b   Musser, James M ^b   Drlica, Karl ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; DNA TOPOISOMERASE (ATP HYDROLYSING); ETHAMBUTOL; ISONIAZID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN;

AMINO ACID SEQUENCE; ARTICLE; BACTERIAL MUTATION; EPIDEMIC; GENE MUTATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; TREATMENT FAILURE; TUBERCULOSIS;

EID: 0029909110     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.5.1127     Document Type: Article

References (15)

1. Frieden T, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen G, Dooley S. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328:521-6.
2. Sullivan EA, Kreiswirth BN, Palumbo L, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995;345:1148-50.
3. Valway SE, Greifinger RB, Papania M, et al. Multidrug-resistant tuberculosis in the New York State prison system, 1990-1991. J Infect Dis 1994; 170:151-6.
4. Drlica-K. Control of bacterial DNA supercoiling. Mol Microbiol 1992;6:425-33.
5. Hooper D, Wolfson J. Mechanisms of bacterial resistance to quinolones. In: Hooper D, Wolfson J, eds. Quinolone antimicrobial agents. Washington, DC: American Society for Microbiology, 1993:97-118.
6. Drlica K, Kreiswirth B. 4-quinolones and the physiology of DNA gyrase. In: Liu L, ed. DNA topoisomerases: molecular targets for chemotherapy of cancer and infectious diseases. San Diego: Academic Press, 1994:263-83.
7. Chen CR, Malik M, Snyder M, Drlica K. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. J Mol Biol 1996;258:627-37.
8. Drlica K, Malik M, Wang JY, Levitz R, Burger R. The fluoroquinolones as antituberulosis agents. In: Rom W, Garay S, eds. Tuberculosis. Boston: Little, Brown, 1995:817-27.
9. Takiff H, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of the Mycobacterium tuberculosis gyrA and gyrB genes, and characterization of quinolone resistance mutations. Antimicrob Agents Chemother 1994;38:773-80.
10. Ferrero L, Cameron B, Manse B, et al. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fiuoroquinolones. Mol Microbiol 1994;13:641-53.
11. van Embden JD, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993;31:406-9.
12. Bifani P, Plikaytis BB, Kapur V, et al. Origin and interstate spread of a New York City multidrug resistant Mycobacterium tuberculosis clone family: adverse implications for tuberculosis control in the 21st century. JAMA 1996;275:452-7.
13. Kapur V, Li LL, Hamrick MR, et al. Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing. Arch Pathol Lab Med 1995;119:131-8.
14. Yoshida, H, Bogaki, M, Nakamura, M, Nakamura, S. Quinolone-resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 1990;34:1271-2.
15. Ng EY, Trucksis M, Hooper D. Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob Agents Chemother 1994;38:1345-55.